gvtcx

Transitional Drugs 7

key details

Value£53,566,932 (£64,280,318 inc. VAT)
Statuscomplete
Category (CPV) 33600000
RegionWales
Procedureopen
SME suitableYes
OCIDocds-h6vhtk-067da4

Awards (10)

This procurement was awarded to 10 suppliers. Values shown are per-award; the notice total is £53,566,932.

SupplierValueDateStatus
Amgen Ltd shared £16,804,001 3 Jun 2026 active
Celix Pharma shared £16,804,001 3 Jun 2026 active
Celltrion Healthcare shared £16,804,001 3 Jun 2026 active
Fresenius Kabi Ltd shared £16,804,001 3 Jun 2026 active
Gedeon Richter UK Ltd shared £16,804,001 3 Jun 2026 active
Hikma Pharmaceuticals International Ltd shared £16,804,001 3 Jun 2026 active
Mercury Pharmaceuticals Ltd shared £16,804,001 3 Jun 2026 active
Novartis Pharmaceuticals UK Ltd shared £16,804,001 3 Jun 2026 active
Roche Products Ltd shared £16,804,001 3 Jun 2026 active
Vifor Pharma UK Ltd shared £16,804,001 3 Jun 2026 active

description

The provision of Drugs that have recently lost exclusivity

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

4 notices published against this procurement.

PublishedTypeRegimeNotice
8 Apr 2026 Preliminary market engagement (UK2) Procurement Act 2023 031798-2026
10 Apr 2026 Tender notice (UK4) Procurement Act 2023 032804-2026
5 Jun 2026 Contract award (UK6) Procurement Act 2023 053158-2026
30 Jun 2026 Contract details (UK7) Procurement Act 2023 061468-2026

more from NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.